Oxalo Therapeutics

Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stones. University of Chicago assistant professor of medicine Hatim Hassan, MD, PhD, studies kidney disease and his research led him to leverage the microbiome to create new ways to prevent kidney stones. He worked with the Polsky Center and was introduced to Yang Zheng, a Chicago Booth student who is now chief operating officer for Oxalo Therapeutics. Together, Hassan and Zheng won $250,000 from the George Shultz Innovation Fund and $25,000 from the New Venture Challenge. Oxalo is currently beginning preclinical development and in the process of raising private capital.


  • Founded by Hatim Hassan, MD, PhD and Yang Zhang
  • Finalists at the 2018 Edward L. Kaplan, ’71,  New Venture Challenge ($25,000)
  • Awarded up to $250,000 at the Fall 2017 George Shultz Innovation Fund Finals
  • Headquartered in Chicago, IL
  • oxalotherapeutics.com

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.